There are a number of specific characteristics to be considered when developing and manufacturing live bacterial vaccines.
Guido Dietrich
Advertisement
Director of bulk technologies at GlaxoSmithKline Biologicals
Articles by Guido Dietrich
Advertisement
Latest Updated Articles
Developing and Manufacturing Attenuated Live Bacterial VaccinesPublished: October 2nd 2008 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
2
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
3
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
4
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
5
